Evidence map›Paper›PMID 18172109›Full record

ArticleInvestigative ophthalmology & visual science2008

Modeling of corneal and retinal pharmacokinetics after periocular drug administration.

Aniruddha C Amrite, Henry F Edelhauser, Uday B Kompella

Open access · greenAbstract read
In one paragraph

Article in Investigative ophthalmology & visual science, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed
6.7field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

26 citing papers in PubMed, 77 citations in OpenAlex.

  1. Trial
  2. Quantitative systems pharmacology of the eye: Tools and data for ocular QSP.CPT: pharmacometrics & systems pharmacology · 2023
    Review
  3. Article
  4. Elastic Fibers/Fabrics for Wearables and Bioelectronics.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2022
    Review
  5. Article
  6. Review
  7. Review
  8. Article
  9. Article
  10. Article
  11. Principles of pharmacology in the eye.British journal of pharmacology · 2017
    Review
  12. Sustained Delivery of Timolol Maleate for Over 90 Days by Subconjunctival Injection.Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics · 2016
    Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Influence of drug solubility and lipophilicity on transscleral retinal delivery of six corticosteroids.Drug metabolism and disposition: the biological fate of chemicals · 2011
    Article
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 2 countries.

Aniruddha C AmriteDepartment of Pharmaceutical Sciences, University of Nebraska Medical Center, Omaha, NE 68198, USA.
Henry F Edelhauser
Uday B Kompella
Pharmaceutical Biotechnology (Czechia) · CZEmory Eye Center · US

Funding

P30-Core Grant for Vision Research Core CP30EY006360 · NEI · EMORY UNIVERSITY · PI NICKERSON, JOHN M · 1986 to 2025
$15.3M
Transscleral Drug Delivery for Retinal DisordersR24EY017045 · NEI · EMORY UNIVERSITY · PI EDELHAUSER, HENRY FRANCIS · 2006 to 2010
$6.9M
Pharmacological Approaches to Treat Diabetic RetinopathyR01DK064172 · NIDDK · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI KOMPELLA, UDAY B · 2003 to 2005
$697k
Subconjunctival Route to Prolong Corticosteroid DeliveryR03EY013842 · NEI · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI KOMPELLA, UDAY B · 2003 to 2005
$441k
Delivery of LEDGF for retinal degenerative disordersR21EY017360 · NEI · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI KOMPELLA, UDAY B · 2007 to 2008
$395k
NEI NIH HHS P30 EY006360NEI NIH HHS R03 EY 013842NEI NIH HHS R03 EY013842NEI NIH HHS R21 EY 017360NEI NIH HHS R21 EY017360NEI NIH HHS R24 EY 017045NEI NIH HHS R24 EY017045NIDDK NIH HHS R01 DK 064172NIDDK NIH HHS R01 DK064172
6 · The paper itself

Abstract

purposeTo develop pharmacokinetics models to describe the disposition of small lipophilic molecules in the cornea and retina after periocular (subconjunctival or posterior subconjunctival) administration.

methodsCompartmental pharmacokinetics analysis was performed on the corneal and retinal data obtained after periocular administration of 3 mg of celecoxib (a selective COX-2 inhibitor) to Brown Norway (BN) rats. Berkeley Madonna, a differential and difference equation-based modeling software, was used for the pharmacokinetics modeling. The data were fit to different compartment models with first-order input and disposition, and the best fit was selected on the basis of coefficient of regression and Akaike information criteria (AIC). The models were validated by using the celecoxib data from a prior study in Sprague-Dawley (SD) rats. The corneal model was also fit to the corneal data for prednisolone at a dose of 2.61 mg in albino rabbits, and the model was validated at two other doses of prednisolone (0.261 and 26.1 mg) in these rabbits. Model simulations were performed with the finalized model to understand the effect of formulation on corneal and retinal pharmacokinetics after periocular administration.

resultsCelecoxib kinetics in the BN rat cornea can be described by a two-compartment (periocular space and cornea, with a dissolution step for periocular formulation) model, with parallel elimination from the cornea and the periocular space. The inclusion of a distribution compartment or a dissolution step for celecoxib suspension did not lead to an overall improvement in the corneal data fit compared with the two-compartment model. The more important parameter for enhanced fit and explaining the apparent lack of an increase phase in the corneal levels is the inclusion of the initial leak-back of the dose from the periocular space into the precorneal area. The predicted celecoxib concentrations from this model also showed very good correlation (r = 0.99) with the observed values in the SD rat corneas. Similar pharmacokinetics models explain drug delivery to the cornea in rat and rabbit animal models. Retinal pharmacokinetics after periocular drug administration can be explained with a four-compartment (periocular space, choroid-containing transfer compartment, retina, and distribution compartment) model with elimination from the periocular space, retina, and choroid compartment. Inclusion of a dissolution-release step before the drug is available for absorption or elimination better explains retinal t(max). Good fits were obtained in both the BN (r = 0.99) and SD (r = 0.99) rats for retinal celecoxib using the same model; however, the parameter estimates differed.

conclusionsCorneal and retinal pharmacokinetics of small lipophilic molecules after periocular administration can be described by compartment models. The modeling analysis shows that (1) leak-back from the site of administration most likely contributes to the apparent lack of an increase phase in corneal concentrations; (2) elimination via the conjunctival or periocular blood and lymphatic systems contributes significantly to drug clearance after periocular injection; (3) corneal pharmacokinetics of small lipophilic molecules can be explained by using similar models in rats and rabbits; and (4) although there are differences in some retinal pharmacokinetics parameters between the pigmented and nonpigmented rats, the physiological basis of these differences has yet to be ascertained.

Indexed as

AnimalsCelecoxibConjunctivaCorneaCyclooxygenase 2 InhibitorsGlucocorticoidsModels, BiologicalPermeabilityPrednisolonePyrazolesRabbitsRatsRats, Inbred BNRats, Sprague-DawleyRetinaSulfonamidesCelecoxibCyclooxygenase 2 InhibitorsGlucocorticoidsPrednisolonePyrazolesSulfonamides

Identifiers

PMID18172109
PMCPMC3324093
OpenAlexW2037425801

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.